TLDR A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
A 15-year-old boy with perifolliculitis capitis abscedens et suffodiens (PCAS) was treated with a combination of adalimumab and baricitinib after initial treatment with adalimumab and isotretinoin proved insufficient. Over 9 months, the patient's condition significantly improved, with almost complete healing of skin lesions and disappearance of most inflammatory alopecia patches. This case represents the first documented successful treatment of PCAS using tumor necrosis factor inhibitors and baricitinib, as no previous reports were found in the literature.
66 citations,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
355 citations,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
48 citations,
January 2014 in “Dermatology Online Journal” New treatments for Dissecting cellulitis show promise, but more research is needed to understand the disease and establish a standard treatment plan.
1 citations,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
May 2023 in “Journal of Clinical Medicine” New understanding and treatments for hair loss are improving, but more research is needed.
12 citations,
January 2021 in “Drugs in R&D” Isotretinoin is effective for treating dissecting cellulitis, but recurrence is common.
1 citations,
July 2012 in “Springer eBooks” The document concludes that more research is needed to better understand and treat scarring hair loss conditions.
